Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OncoSil Medical Ltd ( (AU:OSL) ) has shared an update.
OncoSil Medical has received a A$1.84 million refund under Australia’s R&D Tax Incentive program for eligible research and development activities conducted in the 2025 financial year, reinforcing government-backed support for its ongoing innovation in pancreatic cancer treatment. The company said the non-dilutive funding will help advance its commercial-stage OncoSil™ device, as management focuses on boosting clinician awareness and adoption to drive sales growth and shareholder value while maintaining fiscal discipline, underlining its efforts to strengthen its position in the niche market for localised pancreatic cancer therapies.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global interventional oncology medical device company focused on improving outcomes for cancer patients through the targeted intratumoural placement of Phosphorous-32 (32P) microparticles alongside chemotherapy. Its lead product, the OncoSil™ device, is designed to treat unresectable locally advanced pancreatic cancer by delivering a higher, localized radiation dose directly into the tumour while sparing surrounding organs, and is approved for sale in more than 30 countries including the EU, UK, Turkey and Israel, with commercial treatments already underway across several European markets.
Average Trading Volume: 21,112
Technical Sentiment Signal: Sell
Current Market Cap: A$17M
See more insights into OSL stock on TipRanks’ Stock Analysis page.